Tango Therapeutics, Inc. Retained Earnings
Tango Therapeutics, Inc. (TNGX) had Retained Earnings of -$704.01 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$704.01M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$648.67M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$603.15M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$564.40M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$704.01M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$648.67M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$603.15M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$564.40M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$580.29M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$541.43M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$501.56M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$463.89M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$434.72M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$409.17M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$371.26M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$340.49M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$318.23M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$297.52M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$269.51M 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$240.45M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$211.40M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | -$186.54M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | -$161.34M 10-K · filed 2023-03-27 | |
| 2021-09-30 | -$139.29M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$1.13M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$362.80K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$103.10M 10-K · filed 2022-03-28 | -$123.05K 10-K · filed 2021-03-31 |
| 2020-09-30 | -$52.86K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |